ImmuneOnco Biopharma

[On Demand]
ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is a clinical-stage
biopharmaceutical company dedicated to development and commercialization of innovative cancer immunotherapy.
The company has established several solid platforms harnessing both innate and adaptive immune cells. Macrophages
play a critical role in fighting cancer through phagocytosis followed by presenting of tumor antigen to T cell. However
cancer cells are smart and can always find a way to evade the surveillance, such as by over-expressing immune
checkpoints including CD47.

ImmuneOnco takes the advantage of the IP-protected SIRPa-domain to develop the mAb-Trap format by which several
bispecific recombinant antibody-receptor proteins have been developed that simultaneously targeting CD47 and other
tumor antigen (TA) such as CD20, Her2, PD-L1, new targets, etc.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
SIRPaD1-Fc (IMM01)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
VP, Business Development
ImmuneOnco Biopharma